A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

NCT06052566 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Steatohepatitis
Hepatic Impairment

Interventions

DRUG: Efinopegdutide

Sponsor

Merck Sharp & Dohme LLC